Long acting GLP-1 receptor agonist (injectable)
Bofanglutide (GZR18) injection
BOFANG_SC
Doses in this pooled treatment
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 3.06 (0.18 to 106) | 0.43 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.80 (0.07 to 74.82) | 0.39 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.85 (0.08 to 75.80) | 0.37 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.10 (0.14 to 14.16) | 0.55 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 0.43 (0.01 to 29.41) | 0.71 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.08 (0.14 to 13.20) | 0.56 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.70 (0.04 to 11.27) | 0.44 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -12.54 (-20.09 to -4.09) | 0.86 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -12.47 (-18.88 to -4.44) | 0.93 |
| Overweight or obesity without diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 1.21 (-7.16 to 9.59) | 0.54 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.82 (0.35 to 17.25) | 0.41 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 6.58 (2.99 to 16.99) | 0.23 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 4.39 (1.75 to 11.87) | 0.53 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.42 (1.09 to 5.72) | 0.39 |
Trials
- NCT06256562A Multicenter, Randomized, Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Chinese Obese/Overweight Patients2023 · 340 randomized · 30 weeks
- NCT06256523A Multicenter, Randomized, Double-blind, Placebo-controlled Phase Ib/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GZR18 Injection in Chinese Adult Patients With Type 2 Diabetes Mellitus (T2DM)2022 · 72 randomized · 26 weeks